Evidence mapPaperPMID 39460977Full record

ReviewDiabetic medicine : a journal of the British Diabetic Association2025

Integrated multiomic analyses: An approach to improve understanding of diabetic kidney disease.

Claire Hill, Amy Jayne McKnight, Laura J Smyth

Abstract readReview
In one paragraph

Review in Diabetic medicine : a journal of the British Diabetic Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Integrated multiomic analyses: An approach to improve understanding of diabetic kidney disease.Diabetic medicine : a journal of the British Diabetic Association · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Claire HillCentre for Public Health, School of Medicine, Dentistry and Biomedical Science, Queen's University Belfast, Belfast, UK.ORCID https://orcid.org/0000-0002-2481-5162
Amy Jayne McKnightCentre for Public Health, School of Medicine, Dentistry and Biomedical Science, Queen's University Belfast, Belfast, UK.
Laura J SmythCentre for Public Health, School of Medicine, Dentistry and Biomedical Science, Queen's University Belfast, Belfast, UK.

Funding

Social Circumstances and Epigenomics Promoting Health in Three CountriesR01AG068937 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · 2023 to 2025
$1.1M
A functional genomics pipeline for genetic discovery in diabetic kidney diseaseR01DK132299 · BROAD INSTITUTE, INC. · 2025 to 2025
$623k
Kidney Research UK (KS_RP_007_20190919)National Institute on Aging NIA (R01AG068937)National Institutes of Health (NIH; R01DK132299)NIA NIH HHS R01 AG068937NIDDK NIH HHS R01 DK132299Science Foundation Ireland (SFI) and the Department for the Economy (DfE, NI) - Investigator Program Partnership Award (15/IA/3152)The Stoneygate Trust (KS_RP_007_20190919)The US-Ireland Research and Development Partnership Programmes by the Health and Social Care Research and Development Division (STL/5569/19; STL/5586/19)UK Research and Innovation (Medical Research Council MC_PC_20026)
6 · The paper itself

Abstract

aimDiabetes is increasing in prevalence worldwide, with a 20% rise in prevalence predicted between 2021 and 2030, bringing an increased burden of complications, such as diabetic kidney disease (DKD). DKD is a leading cause of end-stage kidney disease, with significant impacts on patients, families and healthcare providers. DKD often goes undetected until later stages, due to asymptomatic disease, non-standard presentation or progression, and sub-optimal screening tools and/or provision. Deeper insights are needed to improve DKD diagnosis, facilitating the identification of higher-risk patients. Improved tools to stratify patients based on disease prognosis would facilitate the optimisation of resources and the individualisation of care. This review aimed to identify how multiomic approaches provide an opportunity to understand the complex underlying biology of DKD.

methodsThis review explores how multiomic analyses of DKD are improving our understanding of DKD pathology, and aiding in the identification of novel biomarkers to detect disease earlier or predict trajectories.

resultsEffective multiomic data integration allows novel interactions to be uncovered and empathises the need for harmonised studies and the incorporation of additional data types, such as co-morbidity, environmental and demographic data to understand DKD complexity. This will facilitate a better understanding of kidney health inequalities, such as social-, ethnicity- and sex-related differences in DKD risk, onset and progression.

conclusionMultiomics provides opportunities to uncover how lifetime exposures become molecularly embodied to impact kidney health. Such insights would advance DKD diagnosis and treatment, inform preventative strategies and reduce the global impact of this disease.

Indexed as

Diabetic NephropathiesBiomarkersDisease ProgressionHumansProteomicsBiomarkersdiabetic kidney diseaseepigeneticsgenomicslipidomicsmetabolomicsproteomicstranscriptomics

Identifiers

PMID39460977
PMCPMC11733670

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.